WHAT IS CLAIMED IS:

1. Use of *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide in the manufacture of a medicament for treating anhedonia in a human in need thereof.

2. Use of *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide in the manufacture of a medicament for reversing hyperactivity in the ventral tegmental area (VTA) in a human in need thereof,

wherein the human is suffering from anhedonia.

3. The use of claim 1 or 2, wherein administration of the medicament enhances the opening of a Kv7 potassium channel in the human.

4. Use of *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide in the manufacture of a medicament for enhancing the opening of a Kv7 potassium channel in a human,

wherein the human is suffering from anhedonia.

5. The use of claim 3 or claim 4, wherein the Kv7 potassium channel is one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5.

6. The use of any one of claims 1-5, wherein the anhedonia comprises:

(a) sexual anhedonia; or

(b) social anhedonia.

7. The use of any one of claims 1-6, wherein the anhedonia is a symptom of a neuropsychiatric disorder.

8. The use of claim 7, wherein the neuropsychiatric disorder is a depressive disorder, substance-related disorder, psychotic disorder, personality disorder, epileptic disorder, or a combination thereof.

9. The use of claim 8, wherein the neuropsychiatric disorder is a depressive disorder.

10. The use of claim 9, wherein the depressive disorder is stress-induced depression, major depressive disorder (MDD), post-traumatic stress disorder (PTSD), disruptive mood dysregulation disorder, persistent depressive disorder, bipolar spectrum disorder, bipolar depression, postpartum depression, premenstrual dysphoric disorder (PMDD), seasonal affective disorder (SAD), atypical depression, treatment-resistant depression (TRD), depression associated with agitation or anxiety, adjustment disorder with depressed mood, prolonged depressive reaction, or a combination thereof.

11. The use of claim 9, wherein the depressive disorder is MDD.

12. The use of claim 7, wherein the neuropsychiatric disorder is a substance-related disorder.

13. The use of claim 12, wherein the substance-related disorder comprises a dependency on alcohol, cocaine, opioids, or nicotine.

14. The use of claim 7, wherein the neuropsychiatric disorder is schizophrenia, extrapyramidal disorder, Alzheimer's disease, dementia, Parkinson's disease, schizoaffective disorder, schizotypal disorder, obsessive-compulsive disorder, PTSD, anorexia nervosa, panic disorder, attention deficit hyperactivity disorder (ADHD), or dysthymic disorder.

15. The use of claim 7, wherein the neuropsychiatric disorder is an epileptic disorder.

16. The use of claim 15, wherein the epileptic disorder is epilepsy, chronic headache including chronic migraine with or without aura, migraine aura without headache, chronic

tension headache, hemicranias continua, new daily persistent headache, post stroke, dementia, multiple sclerosis, cancer, chronic pain, HIV/AIDs, lupus, or hypothyroidism.

17. The use of any one of claims 1-16, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be orally administered to the human.

18. The use of any one of claims 1-17, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be administered to the human at a dose of:

(a) 2 to 200 mg;

(b) 5 to 100 mg;

(c) 5 to 80 mg; or

(d) 5 to 40 mg.

19. The use of any one of claims 1-17, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be administered to the human in a dosage unit of:

(a) 5 mg;

(b) 10 mg;

(c) 15 mg;

(c) 20 mg; or

(d) 25 mg.

20. The use of any one of claims 1-17, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be administered to the human at a dose of:

(a) 5-1000 mg per day or per week;

(b) 5-500 mg per day or per week; or

(c) 5-250 mg per day or per week.

21. The use of claim 20, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be administered at a dose of:

(a) 5-150 mg per day to the human; or

(b) 100 mg per day to the human.

22. The use of any one of claims 1-14, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be administered at a dose of:

(a) 0.05-20 mg/kg to the human; or

(b) 0.1-5 mg/kg to the human.

23. The use of any one of claims 1-22, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is to be orally administered to the human:

(a) from between about 30 minutes before to about 2 hours after eating a meal; or

(b) during a meal or within 15 minutes after eating a meal.

24. The use of any one of claims 1-23, wherein the anhedonia, prior to treatment with the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide, has a severity of at least:

(a) 5 as measured by the Snaith-Hamilton Pleasure Scale (SHAPS); or

(b) 9 as measured by SHAPS.